Saturday, February 13, 2016

All about Simon!

Jan 25, 2016 ... UnitedHealth is based in Minnesota , home of the famous Mayo Clinic and Simon Stevens is married to an American and they have school age ...
cockroachcatcher.blogspot.com
Jan 7, 2016 ... I have always admired Simon Stevens and his ability to quickly picked some of the best loved people in the NHS to promote Vanguard. The like ...
cockroachcatcher.blogspot.com
Nov 5, 2015 ... The unveiling two days ago of Simon Stevens as the new chief executive of NHS England prompted widespread relief, a broad consensus that ...
cockroachcatcher.blogspot.com
Mar 13, 2015 ... NHS boss Stevens is a powerful figure in all of this. Since the 2012 Act dramatically reduced ministerial accountability for the NHS, the NHS ...
cockroachcatcher.blogspot.com

Oct 24, 2013 ... Now Stevens is to play a crucial role in presenting the more responsible face of American healthcare and in persuading the key players in ...
cockroachcatcher.blogspot.com
Aug 28, 2015 ... As Stevens noted in his forward view, there is considerable consensus about what needs to change to improve care and health: “The traditional ...
cockroachcatcher.blogspot.com
Oct 8, 2015 ... And Stevens' PACS (part of Vanguard) are explicitly modelled on San Francisco's Kaiser Permanante's Accountable Care Organisation model ...
cockroachcatcher.blogspot.com
Feb 3, 2016 ... As Stevens noted in his forward view, there is considerable consensus about what needs to change to improve care and health: “The traditional ...
cockroachcatcher.blogspot.com









Sep 7, 2015 ... Simon Stevens spent some years in the US. Is Vanguard a re-working of Kaiser Permanente? Ray of hope from USA? California©2007 Am Ang ...
cockroachcatcher.blogspot.com
Jun 9, 2015 ... As Stevens noted in his forward view, there is considerable consensus about what needs to change to improve care and health: “The traditional ...
cockroachcatcher.blogspot.com
Oct 5, 2015 ... NHS & Wine: Simon Stevens----Sell or Sail? Hospital Based NHS: ... David Cameron & SimonStevens: Tannhäuser & Vangua... NHS: The Last ...
cockroachcatcher.blogspot.com
Jan 25, 2008 ... David Cameron & Simon Stevens: Tannhäuser & Vanguard! The thing that hath ... Simon Stevensspent some years in the US. Is Vanguard a ...
cockroachcatcher.blogspot.com


Nov 1, 2015 ... NHS & Simon Stevens: From UnitedHealth to JCPenney... New York .... NHS & Wine: SimonStevens----Sell then Sail? Dr No: Is this the sound ...
cockroachcatcher.blogspot.com
Sep 14, 2009 ... “When I was at Oxford taking PPE 20 years ago, my best friend was Simon Stevens, who went on to become Tony Blair's key health policy ...
cockroachcatcher.blogspot.com
Apr 19, 2015 ... Simon Stevens & Vanguard: Jung & JCPenney! Save the NHS: Control Health ... Simon Stevens: NHS England & UnitedHealth! NHS & David ...
cockroachcatcher.blogspot.com
Oct 19, 2014 ... October (10). NHS & Wine: Simon Stevens----Sell then Sail? .... David Cameron & Simon Stevens: Tannhäuser & Vanguard! The thing that hath ...
cockroachcatcher.blogspot.com
Jan 6, 2016 ... Ex-Blair: Patricia Hewitt: now with Cinven (Bupa Hospitals). Simon Stevens: now with UnitedHealth · McKinsey: Galleon, Railtrack & The NHS.
cockroachcatcher.blogspot.com
Oct 23, 2014 ... ... an unbiased presentation of the risks and benefits. So please Mr Hunt and Mr Stevens, can we get the doctors to think NPH before Dementia!
cockroachcatcher.blogspot.com
Oct 27, 2015 ... NHS & Wine: Simon Stevens----Sell or Sail? Hospital Based NHS: ... David Cameron & SimonStevens: Tannhäuser & Vangua... NHS: The Last ...
cockroachcatcher.blogspot.com
Jan 30, 2016 ... NHS & Simon Stevens----Sell or Sail? Tosca & NHS: ... Ecclesiastes & Simon Stevens: Tannhäuser & Vangua... Hunt & Junior Doctors ...
cockroachcatcher.blogspot.com



Tuesday, February 2, 2016

Old but still gold: Lithium in stabilizing the mood



http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755168/
Many, if not all, great discoveries in psychopharmacology resulted, as Donald Klein noted,[] “from chance observations of unexpected clinical benefits or as inadvertent outcomes of blind pharmaceutical searches.” One of such discoveries, by Cade J[] in the late 1940's, was the calming anti-manic effect of lithium. Cade first noticed a calming effect of lithium in guinea pigs. He decided to test lithium in various mental illnesses, including mania and melancholia (interestingly, he ingested lithium himself first to ensure its safety in humans). The calming effect of lithium in mania was very robust, and Cade even speculated that mania may be caused by some lithium deficiency. His seminal discovery ultimately led to a revolutionary new approach - we not only had and have an agent to treat mania and manic-depressive illness (what we call today a bit strangely bipolar illness), but we got an agent that is useful to prevent future episodes of this illness and to stabilize fluctuations of mood. However, one should note that William Hammond first reported on the usefulness of lithium in manic states as early as in 1871, which has not been mentioned in the textbooks.[]
While Cade[] is rightfully given credit for the discovery of the anti-manic properties of lithium, it is not clear whether this discovery would not have remained just an interesting observation without wide-scale clinical application but for the work of other giants of the golden era of psychopharmacology. The main student and proponent of lithium use was the Danish psychiatrist Mogens Schou (1918-2005). Schou started to examine the clinical properties of lithium as a young psychiatrist during the early 1950's. Lithium remained his “life-long obsession.” In his early exploration of lithium, he designed one of the first partly open and partly randomized and placebo-controlled trials of this agent. His early research confirmed the previous finding that lithium has anti-manic properties.[] Schou spent endless time researching all aspects of lithium's effect on the body and the brain, and published on a wide range of issues, from lithium in the heart muscle, to lithium's teratogenicity, and the effect of prolonged lithium administration on cerebral monoamine neurons in rats. His work cemented the role for lithium in the prophylaxis of manic-depressive illness, in spite of a lot of doubts and opposition (especially among the British psychiatrists). He published well over 500 articles on lithium. He remained an unfettered defender of lithium's use during the attacks on lithium, doubts about its efficacy, reports of its toxicity and possible teratogenicity. He has published excellent summaries and “anniversary,” articles on lithium treatment.[]
In the recent era, when many new agents are being proposed (mainly by the pharmaceutical industry) as “mood stabilizers,” some may ask, “so what, there are other, easier to use mood stabilizers.” True, we have many other medications, such as valproic acid, carbamazepine, and several other anticonvulsants and antipsychotics, used as anti-manic agents or mood stabilizers. However, as Schou[] and others pointed out, the prophylactic effect of these so called mood stabilizers remains either weak or missing. Lithium remains a unique agent, the gold standard among the so called mood stabilizers. As Bauer and Mitchner[] stated in their review, the evidence supports a role for lithium as a first-line agent for the treatment of manic-depressive (bipolar) disorder. They proposed a “two-by-two” definition, which considers an agent a mood stabilizer if it has efficacy in treating acute manic and depressive symptoms, and prevents manic and depressive symptoms in manic-depressive disorder. After their extensive review of mood stabilizer trials,[] they concluded that among “mood stabilizers”, only lithium fulfilled the a priori definition of a mood stabilizer (relaxing their quality criterion did not change this finding). It is important to note that they also pointed out that lithium monotherapy has been the exception rather than the rule.
The most serious outcome of manic-depressive illness is suicide. Interestingly, several reports during the last decade indicated that lithium, in addition to its mood stabilizing and other properties also possesses an anti-suicidal effect in bipolar disorder patients. Tondo and colleagues[] in their large observational study found that lithium maintenance was associated with marked reduction in life-threatening suicidal acts - and that the numbers of these acts sharply increased after lithium discontinuation. Although treatment with other mood stabilizers may also lead to the reduction of suicide rates, it seems that lithium may have some superiority in relation to the prevention of suicide.[]
Thus lithium is not only a unique mood stabilizer that meets various standards proposed for mood stabilizers, but also helps to prevent the most serious complication of mood disorders - suicide. Competent clinicians should continue using lithium in the treatment of acute episodes of manic-depressive illness as well as in the prophylaxis of it. Its benefits usually outweigh the side effects and other difficulties with laboratory tests for lithium levels. As long as patients are evaluated regularly for lithium's side effects on the thyroid gland and kidneys, lithium will remain as an agent that has substantial prophylactic and therapeutic effect in manic-depressive illness. As Mogens Schou[] noted several years ago, “the clinical, methodological, economical, and human benefits of prophylactic lithium treatment are vast.” And as they remain vast, competent clinicians should not deprive their manic-depressive patients of the benefit of this still uniquely effective and fairly cheap agent.

Footnotes


Cade, John Frederick Joseph (1912–1980)


This article was published in Australian Dictionary of Biography, Volume 13, (MUP), 1993
John Frederick Joseph Cade (1912-1980), medical scientist, was born on 18 January 1912 at Horsham, Victoria, son of David Duncan Cade, medical practitioner, and his wife Ellen, née Edwards, both Victorian born. David commanded the 3rd Field Ambulance, Australian Imperial Force, during World War I and was awarded the Distinguished Service Order. In 1932 he became medical superintendent at Sunbury Mental Hospital.
Educated at Scotch College and the University of Melbourne (M.B., B.S., 1934; M.D., 1938), John was a resident medical officer at St Vincent's Hospital in 1935 and at the Royal Children's Hospital in 1936. That year he joined the mental hygiene branch of the Department of the Chief Secretary and was appointed medical officer at Mont Park Mental Hospital. At St Patrick's Catholic Cathedral, Melbourne, on 1 November 1937 he married Estana Evelyn Jean Charles, a double-certificated nurse; they were to have four sons and a daughter.
Having served in the Militia from 1935, Cade was appointed captain, Australian Army Medical Corps, A.I.F., on 1 July 1940 and posted to the 2nd/9th Field Ambulance. He arrived in Singapore in February 1941 and was promoted major in September. From February 1942 to September 1945 he suffered the privations of a prisoner of war in Changi camp.
Demobilized on 2 January 1946, Cade returned to the mental hygiene branch, now in the Department of Health, becoming medical superintendent and psychiatrist at the Repatriation Mental Hospital, Bundoora. Suspecting that some excessive toxin in the urine of manic patients was a product of metabolic disorder, he experimented on guinea-pigs with a disused hospital kitchen as his laboratory. He found that the animals became extremely lethargic and were protected from the toxicity of injected urea when lithium carbonate was given simultaneously. Taking lithium himself with no ill effect, he then used it to treat ten patients with chronic or recurrent mania, on whom he found it to have a pronounced calming effect. Cade's remarkably successful results were detailed in his paper, 'Lithium salts in the treatment of psychotic excitement', published in the Medical Journal of Australia (1949). He subsequently found that lithium was also of some value in assisting depressives. His discovery of the efficacy of a cheap, naturally occurring and widely available element in dealing with manic-depressive disorders provided an alternative to the existing therapies of shock treatment or prolonged hospitalization.
In 1952 Cade was appointed psychiatrist superintendent and dean of the clinical school at Royal Park Psychiatric Hospital. Two years later, at the request of the Mental Hygiene Authority which was planning to remodel Royal Park, he visited Britain for six months to inspect psychiatric institutions. On his return, he introduced modern facilities and replaced the rather authoritarian approach to patient care with a more personal and informal style that included group therapy. Concerned at the number of alcohol-related cases, he supported voluntary admission to aid early detection and later proposed the use of large doses of thiamin in the treatment of alcoholism.
Active in professional organizations, Cade was a foundation fellow (1963), State chairman (1963-80) and national president (1969-70) of the (Royal) Australian and New Zealand College of Psychiatrists, and a member (1970-80) of the Medical Board of Victoria. In 1977 he retired from his hospital appointments.
Although the use of lithium revolutionized the treatment of manic-depressive disorders from the 1960s, it was not until 1970 that Cade gained international recognition for his work. That year he received the psychiatric award of the Taylor Manor Hospital, Maryland, United States of America, and was made a distinguished fellow of the American Psychiatric Association. In 1974 he shared the second international award of the Kittay Scientific Foundation in New York with the Danish professor Mogens Schou, whose large clinical trials had validated Cade's research. Appointed A.O. in 1976, Cade was guest of honour that year at an international lithium conference held at New York University's school of medicine.
An 'honourable, upright Christian gentleman', Cade had a mordant sense of humour and an unassuming, rather withdrawn manner. He was modest about his discovery: in his book, Mending the Mind (1979), he discussed the use of lithium treatment without mentioning his own part in it. Survived by his wife and sons, he died of cancer on 16 November 1980 at Fitzroy and was buried in Yan Yean cemetery. A portrait by Max Middleton is held by the family.
Recognition of Cade's pioneering work continued after his death. In 1980 the first John Cade memorial lecture was delivered by Professor Schou at the congress in Jerusalem of the Collegian International Psychopharmacologium (of which Cade had been made an honorary member earlier that year). The John Cade award was inaugurated in 1982 by the Victorian branch of the R.A.N.Z.C.P. and in 1983 the faculty of medicine at the University of Melbourne established the John Cade memorial prize. In 1985 the American National Institute of Mental Health estimated that Cade's discovery of the efficacy of lithium in the treatment of manic depression had saved the world at least $US 17.5 billion in medical costs.